FDA approves Alexion's Strensiq

FDA approved Strensiq asfotase alfa from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP) and granted the company a Priority Review voucher through the agency's rare pediatric disease Priority Review voucher program.

Alexion plans to launch Strensiq next week. Spokesperson Kim Diamond said the company will discuss the drug's price and its plans for the voucher on a conference call on Monday, Oct. 26. ...